Abstract:Abstract 4838 BACKGROUND: The aim of this study was to determine the safety, tolerance and efficacy of linezolid for the treatment of infections from Gram-positive bacteria in immunocompromised patients with Hematological Malignancy. METHODS: This was a prospective non-comparative unblinded and multi-center study in the Hematology Unit over a one-year period, administering combined use of linezolid in patients with Hematological Malignancy. RESULTS: Fifth-four adult patients received linezolid (600 mg, iv, q12h per day). Thirty-four children received linezolid (30 mg/kgr: 3 i.v. per day).Mean duration of linezolid administration was 12.8 days (range, 10–23days). Among the evaluable patients, fifty four were adults, the median age was 67(range, 30–101years); thirty four were children (range, 11 months-12.6 years), while the median age was 6 years. Primary diagnosis was acute lymphoblastic leukemia (forty-five patients), lymphoma (twenty-three patients), multiple myeloma (eleven patients), Aplastic anemia(four patients), myelodysplasia syndrome(one patients), leucopenia and hemophagocytic syndrome (two patient each). All patients were immunocompromised, 90% of them in the midst of chemotherapy cycles. The mean base number of platelet was 41×109/L(range, 30 – 138×109/L), platelet count less than 30×109/L patients were 28 cases (33%), among them, less than 10×109/L were 13 cases (14.8%). 27 out of 88 patients had positive blood cultures, methicillin-resistant Staphylococcus aureus, eighteen patients; Enterococcus, seven patients; Methicillin Resistant Staphylococcus Epidermidis and hemolytic streptococcus (one patient each).All patients were considered clinically cured after the end of the linezolid regimen (100% efficacy). The main adverse events were thrombocytopenia. There were 11 cases happened transient thrombocytopenia, Among them, four cases were happened within 4 days, seven cases happened four to seven days after received linezolid. Eliminate the possibility caused by reasons such as severe infection which can also result in thrombocytopenia, Linezolid related thrombocytopenia were only two cases (2.3%). Chemotherapy-induced myelotoxicity (90% patients) was not worsened during linezolid therapy. The platelet recovery time was also not lengthened during linezolid therapy. No bleeding episodes were presented, no Self-limited diarrhea were happened. The total adverse event rate was 2.3%; however, there was no premature cessation of linezolid in any patient. CONCLUSIONS: Linezolid may be another effective and safe therapy to treat infections from resistant Gram-positive bacteria in immunocompromised patients, even in children. Disclosures: No relevant conflicts of interest to declare.

Analysis of thrombocytopenia induced by combined use of linezolid with sulfas in one patient

High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid

Analysis of the Effect Factors of Thrombocytopenia Associated with Linezolid

Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy.

Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study

Venetoclax Dose Adjustment Due to Drug-Drug Interactions: a Case Report and Literature Review

Meta-analysis of Risk Factors for Thrombocytopenia Related to Linezolid

Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions?

Aanalysis of liver injury induced by linezolid combined with caspofungin (one case)

Development and Validation of a Risk Prediction Model of Linezolid-induced Thrombocytopenia in Elderly Patients

Clinical efficacy of linezolid used by the elderly with renal dysfunction and its effect on platelets

Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: A case report.

Retrospective Analysis of Risk Factors for Cefoperazone/Sulbactam-Induced Thrombocytopenia in Adult Chinese Patients: A Six-Year Real-World Study

The clinical features and drug resistance of 10 patients with linezolid-nonsusceptible Enterococcal blood stream infection

Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia

Bleeding Complications in Vancomycin-Induced Thrombocytopenia: A Real-World Postmarketing Pharmacovigilance Analysis

Clinical drug interactions between linezolid and other antibiotics: For adverse drug event monitoring

Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia

Efficacy and Safety of Linezolid in Immunocompromised Patients with Hematological Malignancy

Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

Prevalence of Potential Drug-Drug Interactions among Intensive Care Unit Patients Receiving Linezolid: a Cross-Sectional Study.